Amendment
The purpose of this modification is to 1 update exhibit b research description document to add scope for a study on H5N1 in cows as authorized by purchase…
$1,995,000
Amendment
As authorized by purchase requisition PR HR0011362430/1, this modification rescopes phase II, at no additional cost to the government, by issuing revision 6…
$0
Amendment
The purpose of this modification is to extend the period of performance of clin 0002, phase II option to september 30, 2024 with no change in cost as…
$0
Amendment
The purpose of this modification is to: (1) replace the darpas cfda number with the darpas assistance listing number (2) update the awardees point of contacts…
$1,038,832
Amendment
The purpose of this modification is to: (1) update the awardees mailing address on the first page of the cooperative agreement in accordance with the address…
$0
Amendment
As authorized by PR HR0011257188, the purpose of this modification is to add funding in the amount of $3,890,801 to incrementally fund the phase II option and…
$3,890,801
Amendment
This modification changes the principal investigator at no change to the estimated amount of the cooperative agreement as requested by the awardee via letter…
$0
Amendment
This modification exercises the phase II option, provides incremental funding of $2,128,400 for phase II and replaces exhibit b, RDD, revision 4 with exhibit b,…
$2,128,400
Amendment
As authorized by PR HR0011151458 and PR HR0011151459, the purpose of this modification is to extend the period of performance due to covid-19 and add…
$5,204,403
Amendment
B6 covid 19 REA. Obligate cares act COVID19 specific funds in the amount of $439,940 via subclin 000802, acrn ad to incrementally fund new phase i base task…
$439,940
Amendment
B6 covid 19 REA. The purpose of this modification is to 1 obligate funds in the amount of $818,099 via subclin 000105, acrn AB $1,337,795 via subclin 000801,…
$2,276,766
Amendment
The purpose of this administrative modification is to issue a correction to the CIN listed in the line of accounting for sub clin 000104 to reflect PR…
$0
Amendment
The purpose of this modification is to obligate funds in the amount of $1,357,506 via subclin 000103, acrn AB and $3,585,413 via subclin 000104, acrn AC,…
Georgia State University Research Foundation Inc.The main goals of this Agreement are the development of synthetic RNA-based activatable RNases to enable prophylactic and therapeutic treatment of SARS-CoV-2…
$712,004
University Of Georgia Research Foundation, Inc.The contractor shall create and utilize an Informatics Core to install hardware and software that maintains non-CUI data security while allowing for ease of…
$3,294,779
Emory UniversityThwarting Influenza with RNA-powered Modulators (ThIRM).
$7,950,909
Duke UniversityThwarting Influenza with RNA-powered Modulators (ThIRM) BASE PERIOD (PHASE I) Heaton (Duke) YEAR 1-TA1 Task 1.1: The contractor shall find targets for…
$3,456,625
The Rockefeller UniversityThe contractor shall find targets for increasing the potency of immune responses via gene modulators in B-cells (Fut8, IRF4, IRF8, ST6Gal1, Il10) and DCs…
$1,132,149
Quick answers
Who received award HR00111920008?
HR00111920008 was awarded to Georgia TECH Research Corp by Defense Advanced Research Projects Agency (Department of Defense) on April 10, 2019.